Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZYN002 for Fragile X Syndrome
ACTRN12621000874819Phase 3Recruiting
- Sponsor
- Zynerba Pharmaceuticals
- Start
- Dec 2021
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in Fragile X syndrome (FXS) comparing ZYN002 with Placebo (2 arms). Primary endpoint: Change in ABC-C(FXS) Pre-Specified Subscale 1 score in patients with complete methylation of the FMR1 gene. Started Dec 2021; status: recruiting.
02
Drugs
Zygel
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on ACTRN12621000874819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000874819.